Navigation Links
BioMed Realty Trust Announces Tax Treatment of 2008 Distributions
Date:1/20/2009

SAN DIEGO, Jan. 20 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced the tax treatment of its 2008 distributions as follows:

                   Security Description: Common Stock
                          CUSIP: 09063H107
                         Ticker Symbol: BMR

                                    Total                    Taxable
       Record       Payable     Distribution   Allocable     Ordinary
        Date         Date         Per Share     to 2008      Dividend

     12/31/2007    1/15/2008      $0.310000    $0.310000     $0.198099
      3/31/2008    4/15/2008      $0.335000    $0.335000     $0.214074
      6/30/2008    7/15/2008      $0.335000    $0.335000     $0.214074
      9/30/2008    10/15/2008     $0.335000    $0.335000     $0.214074
             Totals               $1.315000    $1.315000     $0.840321


                                              Long-Term    Unrecaptured
      Record       Payable       Return of     Capital     Section 1250
       Date          Date         Capital        Gain          Gain

     12/31/2007    1/15/2008     $0.111901     $0.000000     $0.000000
      3/31/2008    4/15/2008     $0.120926     $0.000000     $0.000000
      6/30/2008    7/15/2008     $0.120926     $0.000000     $0.000000
      9/30/2008    10/15/2008    $0.120926     $0.000000     $0.000000
             Totals              $0.474679     $0.000000     $0.000000


        Security Description: 7.375% Series A Cumulative Redeemable
                             Preferred Stock
                              CUSIP: 09063H206
                          Ticker Symbol: BMR PR A

                                   Total                Taxable
       Record       Payable    Distribution  Allocable  Ordinary
        Date         Date        Per Share    to 2008   Dividend

     12/31/2007    1/15/2008     $0.460940   $0.460940   $0.460940
      3/31/2008    4/15/2008     $0.460940   $0.460940   $0.460940
      6/30/2008    7/15/2008     $0.460940   $0.460940   $0.460940
      9/30/2008    10/15/2008    $0.460940   $0.460940   $0.460940
             Totals               $1.84376    $1.84376    $1.84376


                                            Long-Term   Unrecaptured
       Record      Payable      Return of     Capital   Section 1250
        Date         Date         Capital      Gain        Gain

     12/31/2007    1/15/2008     $0.000000   $0.000000   $0.000000
      3/31/2008    4/15/2008     $0.000000   $0.000000   $0.000000
      6/30/2008    7/15/2008     $0.000000   $0.000000   $0.000000
      9/30/2008    10/15/2008    $0.000000   $0.000000   $0.000000
             Totals              $0.000000   $0.000000   $0.000000


The distributions payable on January 15, 2009 to shareholders of record on December 31, 2008, as previously announced on December 15, 2008, are considered 2009 distributions for federal income tax purposes.

The company did not incur any foreign taxes during 2008. In addition, only for purposes of calculating alternative minimum taxable income under Section 55 of the Internal Revenue Code of 1986, as amended, the company apportions $0.0009 per common share and Series A preferred share attributable to depreciation, each assuming a full year of ownership. Stockholders are encouraged to consult with their personal tax advisors as to their specific tax treatment of BioMed Realty Trust distributions.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 69 properties, representing 112 buildings with approximately 10.4 million rentable square feet, including approximately 1.4 million square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Alpine Biomed Acquires Stellate to Create New Leader in Neurology Diagnostics Market
2. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer
3. Collexis BiomedExperts Hits 80,000 Registered Users Within the First Year!
4. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
5. Stem Cells Poised to Grow Organs for Transplant : Zannos Grekos, MD Presents Clinical Data of Research with Adult Stem Cells to Physicians at International Regenerative Biomedicine Conference
6. Response Biomedical Corporation Announces Change of Executives
7. AutismActionPlan.org Launches Doctor-Driven Biomedical Autism Treatment Website
8. LA BioMed researchers among Southern California Super Doctors
9. ASH Holds a Special Symposium to Interest High School Students in Biomedical Research
10. ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research
11. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... ... exhibitor at Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As ... showcase its anatomic and molecular pathology workflow solution, as well as its new ...
(Date:2/17/2017)... ... 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from around the ... - 23 in Beaver Creek, CO. It was announced today by Cindy Lovelace, executive ... Beaver Creek, hosting over 60 faculty members and addressing unmet needs of the NET ...
(Date:2/17/2017)... ... February 17, 2017 , ... Dillon Ruxton ... families and business owners in the greater Fort Lauderdale metropolitan region, is embarking ... For more than 30 years, LifeNet 4 Families has provided a broad range ...
(Date:2/16/2017)... ... February 17, 2017 , ... For some cancer ... their final treatments. Physician researchers at The Marcus Institute of Integrative Health ... for efficacy in reducing symptoms of traumatic stress in cancer patients and ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... planning services to families and entrepreneurs in the Birmingham area, is announcing an ... who needs assistance with her medically challenged son, Anius. , Anius is medically ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Feb. 17, 2017  BioDigital, Inc., creators of ... of their 3D body mapping technology with eClinicalWorks, ... new integration will be used to capture and ... of the human body. BioDigital pilots show using ... while also increasing the precision of clinical annotations ...
(Date:2/17/2017)... -- Noble Capital Markets announced today that it has initiated ... EPIX ). The report was issued by Noble,s Head ... ESSA Pharmaceuticals is a clinical stage biopharmaceutical company ... lead compound EPI-506, is a small molecule oral drug ... receptor, thereby has potential to overcome some of the ...
(Date:2/16/2017)... 16, 2017 Research and Markets has ... Medical Device Technologies" report to their offering. ... Traditional medical ... general instruments, non-drug coated implantables, large endoscopes, needle based drug ... over the last two to three decades for the treatment ...
Breaking Medicine Technology: